Abstract
The prognosis of non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE) due to pleural carcinomatosis is said to be poor. Several reports discussed that the anti-VEGF antibody had the effect of decreasing vascular permeability and reducing pleural effusion. Ramucirumab (RAM), a VEGFR-2 antibody that inhibits tumor angiogenesis, is widely used with docetaxel (DTX) after failure of platinum doublet chemotherapy. Presently, there is no data concerning the tolerable safety profile and efficacy of administering RAM+DTX to patients with NSCLC with MPE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
